{"prompt": "['Secondary Objectives', 'Corresponding Endpoints', 'To evaluate patient assessed satisfaction with', 'Patient responses to Question 1 of the TASQ-', 'route of administration of pertuzumab and', 'SC and TASQ-IV', 'trastuzumab FDC SC and route of', 'administration of P+H IV', \"To evaluate patients' choice of pertuzumab and\", 'Proportion of patients who select pertuzumab', 'trastuzumab FDC SC for the Treatment', 'and trastuzumab FDC SC for the study', 'Continuation Period', 'Treatment Continuation Period', 'To evaluate HCP perception of time/resource', 'HCP responses to the HCPQs, by individual', 'use and convenience with pertuzumab and', 'question', 'trastuzumab FDC SC', 'To evaluate HRQoL with pertuzumab and', 'Change in symptoms and function from', 'trastuzumab FDC SC and P+H IV', 'baseline and over time as assessed by EORTC', 'QLQ-C30 scores', 'Mean and mean changes from baseline score', 'in HRQoL by cycle as assessed by the Global', 'Health Status / overall QoL scale (items 29 and', '30) of the EORTC QLQ-C30.', 'Secondary Safety Objectives', 'Corresponding Endpoints', 'To evaluate the safety and tolerability of', 'Incidence, nature and severity of all AEs,', 'pertuzumab and trastuzumab FDC SC and P+H', 'Grade 3 AEs, SAEs and cardiac AEs', 'IV during the study Treatment Cross-over', '(including LVEF events) with severity', 'Period and the entire adjuvant treatment period', 'determined according to NCI CTCAE v4.0', '(Treatment Cross-over Period + Treatment', 'Incidence of premature withdrawal from study', 'Continuation Period)', 'treatment', 'Targeted vital signs and physical findings', 'Targeted clinical laboratory test results', 'To evaluate the safety of switching from', 'Incidence, nature and severity of all AEs,', 'pertuzumab and trastuzumab FDC SC to P+H', 'Grade 3 AEs, SAEs and cardiac AEs', 'IV and from P+H IV to pertuzumab and', '(including LVEF events) with severity', 'trastuzumab FDC SC', 'determined according to NCI CTCAE v4.0', 'during the study Treatment Cross-over Period', 'by treatment arm', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '17 / Protocol MO40628, Version 42']['Secondary Efficacy Objective', 'Corresponding Endpoints', 'To evaluate the long-term efficacy of the', 'IDFS, defined as the time from randomization', 'pertuzumab and trastuzumab FDC SC and', 'to the first occurrence of one of the following', 'P+H IV', 'events:', 'Ipsilateral invasive breast tumour', 'recurrence (i.e., an invasive breast cancer', 'involving the same breast parenchyma as', 'the original primary lesion)', 'Ipsilateral local-regional invasive breast', 'cancer recurrence (i.e., an invasive breast', 'cancer in the axilla, regional lymph nodes,', 'chest wall, and/or skin of the ipsilateral', 'breast)', 'Distant recurrence (i.e., evidence of', 'breast cancer in any anatomic site other', 'than the two above mentioned sites that', 'has either been histologically confirmed', 'or clinically diagnosed as recurrent', 'invasive breast cancer)', 'Contralateral invasive breast cancer', 'Death attributable to any cause, including', 'breast cancer, non-breast cancer, or', 'unknown cause (but cause of death', 'should be specified, if possible)', 'Note: Ipsilateral or contralateral in situ disease', 'and second primary non-breast cancers', '(including in situ carcinomas and non-', 'melanoma skin cancers) will not be counted as', 'recurrence.', 'IDFS including second primary non-breast', 'cancer, defined as IDFS with second primary', 'non-breast invasive cancer (with the exception', 'of non-melanoma skin cancers and in situ', 'carcinoma of any site) included as an event', 'DDFS, defined as the time from randomization', 'to the date of distant breast cancer recurrence', 'OS, defined as the time from randomization to', 'death from any cause.', 'AE: adverse event; DDFS: distant disease-free survival; EORTC QLQ-C30: European Organization', 'for Research and Treatment of Cancer Quality of Life Questionnaire C30; HCP: healthcare', 'professional; HCPQ: Healthcare Professional Questionnaire; HRQoL: health-related quality of life;', 'IDFS: invasive disease-free survival; LVEF: left ventricular ejection fraction; NCI CTCAE v4.0:', 'National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; OS: overall', 'survival; P+H IV: intravenously administered Perjeta and Herceptin formulations; FDC SC: fixed-dose', 'combination of pertuzumab and trastuzumab for subcutaneous use; PPQ: Patient Preference', 'Questionnaire; QoL: quality of life; SAE: serious adverse event; TASQ-IV/SC: Therapy Administration', 'Satisfaction Questionnaire-intravenous/subcutaneous', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '18 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}